← back to search

Edward C. Smith

KU Leuven · BE
Area of research
Molecular Biology · Aerospace Engineering
Research interest
Research interests include Medicine, Duchenne muscular dystrophy, Spinal muscular atrophy, Internal medicine, Genetics, and Clinical endpoint.
h-index
citations
1,649
works
21
NIH funding
primary concept
email

Recent publications

AAV mini-dystrophin gene therapy for Duchenne muscular dystrophy: a phase 1b trial
Nature Medicine 2025cited by 14position: lastdoi
Complement activation in a phase Ib study of fordadistrogene movaparvovec for Duchenne muscular dystrophy
Molecular Therapy 2025cited by 10position: middledoi
Cardiac safety of fordadistrogene movaparvovec gene therapy in Duchenne muscular dystrophy: Initial observations from a phase 1b trial
Molecular Therapy 2025cited by 9position: middledoi
<i>SPTSSA</i> variants alter sphingolipid synthesis and cause a complex hereditary spastic paraplegia
Brain 2023cited by 34position: middledoi
Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy
JAMA Neurology 2022cited by 124position: middledoi
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial
The Lancet Neurology 2021cited by 470position: middledoi
Phenotypic expansion of CACNA1C-associated disorders to include isolated neurological manifestations
Genetics in Medicine 2021cited by 49position: middledoi
Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping
JAMA Neurology 2020cited by 258position: middledoi
The care of patients with Duchenne, Becker, and other muscular dystrophies in the <scp>COVID</scp>‐19 pandemic
Muscle & Nerve 2020cited by 69position: middledoi
An autosomal dominant neurological disorder caused by de novo variants in FAR1 resulting in uncontrolled synthesis of ether lipids
Genetics in Medicine 2020cited by 49position: middledoi
Clinical sites of the Undiagnosed Diseases Network: unique contributions to genomic medicine and science
Genetics in Medicine 2020cited by 42position: middledoi
Spinal muscular atrophy care in the COVID‐19 pandemic era
Muscle & Nerve 2020cited by 37position: middledoi
Gene therapy as a potential therapeutic option for Duchenne muscular dystrophy: A qualitative preference study of patients and parents
PLoS ONE 2019cited by 44position: middledoi
AVXS-101 Gene Replacement Therapy (GRT) for Spinal Muscular Atrophy Type 1 (SMA1): Pivotal Phase 3 Study (STR1VE) Update
2019cited by 2position: middledoi
Loss of tubulin deglutamylase <scp>CCP</scp> 1 causes infantile‐onset neurodegeneration
The EMBO Journal 2018cited by 126position: middledoi
IRF2BPL Is Associated with Neurological Phenotypes
The American Journal of Human Genetics 2018cited by 115position: middledoi
A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy
Neurology 2017cited by 73position: middledoi
Looking beyond the exome: a phenotype-first approach to molecular diagnostic resolution in rare and undiagnosed diseases
Genetics in Medicine 2017cited by 52position: middledoi
Clinical trial of L‐Carnitine and valproic acid in spinal muscular atrophy type I
Muscle & Nerve 2017cited by 29position: middledoi
Targeted Re-Sequencing Emulsion PCR Panel for Myopathies: Results in 94 Cases
Journal of Neuromuscular Diseases 2016cited by 20position: middledoi
Assessment of obstetric brachial plexus injury with preoperative ultrasound
Muscle & Nerve 2015cited by 23position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Perry B. Shieh · Veterans Affairs Canada6 papers (2019–2025)Anne M. Connolly · Nationwide Children's Hospital5 papers (2019–2021)Russell J. Butterfield · University of Utah5 papers (2020–2025)Michael Binks · Universitat de Barcelona3 papers (2025–2025)David Lévy · University of Chicago3 papers (2025–2025) · 3 papers (2025–2025)Kelly A. Ryan · University of Michigan–Ann Arbor3 papers (2025–2025)Nancy L. Kuntz · Northwestern University3 papers (2019–2021)Thomas O. Crawford · Johns Hopkins University3 papers (2017–2021)Vamshi K. Rao · The Ohio State University3 papers (2020–2020) · 3 papers (2025–2025)Basil T. Darras · Boston Children's Hospital2 papers (2019–2021)Richard S. Finkel · Veterans Affairs Canada2 papers (2020–2021)Eric P. Hoffman · Veterans Affairs Canada2 papers (2016–2020) · 2 papers (2019–2021)Julie Parsons · University of Colorado Boulder2 papers (2020–2020)Claudia A. Chiriboga · Columbia University Irving Medical Center2 papers (2019–2021)Craig M. Zaidman · Pediatrics and Genetics2 papers (2020–2021)Thomas A. Macek · Inotek Pharmaceuticals (United States)2 papers (2019–2021)Emma Ciafaloni · University of Rochester Medical Center2 papers (2020–2020)